BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+4.49%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$9.36B
AUM Growth
+$9.36B
(-3%)
Cap. Flow
+$5.03M
Cap. Flow
% of AUM
0.05%
Top 10 Holdings %
Top 10 Hldgs %
76.51%
Holding
102
New
8
Increased
20
Reduced
5
Closed
7
Top Buys
| 1 |
Insmed
INSM
|
$40.8M |
| 2 |
GRAL
GRAIL, Inc. Common Stock
GRAL
|
$29.1M |
| 3 |
Candel Therapeutics
CADL
|
$25.9M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
$20.8M |
| 5 |
CRISPR Therapeutics
CRSP
|
$18.3M |
Top Sells
| 1 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$192M |
| 2 |
Rhythm Pharmaceuticals
RYTM
|
$17.6M |
| 3 |
Tango Therapeutics
TNGX
|
$5.78M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
$5.31M |
| 5 |
Alector
ALEC
|
$4.32M |
Sector Composition
| 1 | Healthcare | 98.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Structure Therapeutics
GPCR
$1.14B
| $9.81M | 0.1% |
361,565
+276,065
| +323% | +$7.49M |
|
|
VERV
52
DELISTED
Verve Therapeutics
VERV
| $9.54M | 0.1% |
1,691,530
| – | – |
|
|
OPT
53
DELISTED
Opthea Limited American Depositary Shares
OPT
| $8.54M | 0.09% |
2,173,622
| – | – |
|
54
TScan Therapeutics
TCRX
$106M
| $8.47M | 0.09% |
2,784,792
| – | – |
|
55
KALA BIO
KALA
$105M
| $8.34M | 0.09% |
1,201,894
+310,559
| +35% | +$2.16M |
|
56
Vir Biotechnology
VIR
$765M
| $7.96M | 0.09% |
+1,084,539
| New | +$7.96M |
|
57
Mirum Pharmaceuticals
MIRM
$3.75B
| $7.88M | 0.08% |
190,476
| – | – |
|
58
Arvinas
ARVN
$580M
| $7.77M | 0.08% |
405,576
| – | – |
|
59
Intellia Therapeutics
NTLA
$1.26B
| $7.51M | 0.08% |
+644,116
| New | +$7.51M |
|
|
TSVT
60
DELISTED
2seventy bio
TSVT
| $7.34M | 0.08% |
2,497,526
| – | – |
|
61
Taysha Gene Therapies
TSHA
$791M
| $6.93M | 0.07% |
4,004,756
| – | – |
|
62
Celldex Therapeutics
CLDX
$1.57B
| $6.26M | 0.07% |
247,644
| – | – |
|
63
Biomea Fusion
BMEA
$114M
| $5.63M | 0.06% |
1,451,990
-656,959
| -31% | -$2.55M |
|
64
Fate Therapeutics
FATE
$115M
| $5.38M | 0.06% |
3,258,402
+260,630
| +9% | +$430K |
|
65
BioNTech
BNTX
$24.1B
| $5.13M | 0.05% |
+45,031
| New | +$5.13M |
|
66
Disc Medicine
IRON
$2.14B
| $4.88M | 0.05% |
+77,050
| New | +$4.88M |
|
67
Relay Therapeutics
RLAY
$709M
| $4.78M | 0.05% |
1,160,117
| – | – |
|
|
CTNM
68
Contineum Therapeutics
CTNM
$297M
| $4.58M | 0.05% |
312,500
| – | – |
|
|
DBVT
69
DBV Technologies
DBVT
$249M
| $4.52M | 0.05% |
1,461,425
-5,845,706
| -80% | -$3 |
|
70
Sagimet Biosciences
SGMT
$239M
| $4.29M | 0.05% |
952,996
-428,902
| -31% | -$1.93M |
|
71
Wave Life Sciences
WVE
$1.27B
| $4.26M | 0.05% |
344,063
| – | – |
|
72
Skye Bioscience
SKYE
$104M
| $4.11M | 0.04% |
1,450,638
+16,004
| +1% | +$45.3K |
|
73
Vaxcyte
PCVX
$4.17B
| $4M | 0.04% |
48,885
| – | – |
|
74
Sana Biotechnology
SANA
$759M
| $3.88M | 0.04% |
2,380,949
| – | – |
|
75
Leap Therapeutics
LPTX
$12M
| $3.37M | 0.04% |
1,172,175
| – | – |
|